Equities research analysts predict that Endologix, Inc. (NASDAQ:ELGX) will post $47.67 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for Endologix’s earnings, with estimates ranging from $47.50 million to $48.00 million. Endologix posted sales of $50.97 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 6.5%. The business is expected to issue its next earnings results after the market closes on Wednesday, August 2nd.
According to Zacks, analysts expect that Endologix will report full-year sales of $47.67 million for the current financial year, with estimates ranging from $193.51 million to $196.40 million. For the next fiscal year, analysts expect that the business will post sales of $209.49 million per share, with estimates ranging from $203.55 million to $216.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Endologix.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. Endologix had a negative return on equity of 48.92% and a negative net margin of 66.43%. The company had revenue of $42.60 million during the quarter, compared to analysts’ expectations of $41.15 million. During the same period in the prior year, the business earned ($0.25) earnings per share. Endologix’s revenue for the quarter was up .5% compared to the same quarter last year.
A number of research firms recently weighed in on ELGX. Royal Bank Of Canada reissued a “hold” rating and set a $5.00 target price on shares of Endologix in a report on Monday. Zacks Investment Research lowered Endologix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 25th. Stifel Nicolaus reissued a “buy” rating and set a $5.50 target price (up from $5.00) on shares of Endologix in a report on Monday, June 5th. Oppenheimer Holdings, Inc. lowered Endologix from an “outperform” rating to a “market perform” rating and set a $6.00 target price on the stock. in a report on Thursday, May 18th. Finally, BMO Capital Markets reissued a “hold” rating and set a $5.00 target price on shares of Endologix in a report on Thursday, May 18th. Ten research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Endologix presently has a consensus rating of “Hold” and a consensus price target of $7.11.
In other news, Director Dan Lemaitre acquired 22,522 shares of the firm’s stock in a transaction on Monday, May 22nd. The shares were purchased at an average cost of $4.43 per share, with a total value of $99,772.46. Following the acquisition, the director now directly owns 68,689 shares in the company, valued at approximately $304,292.27. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Guido J. Neels acquired 20,000 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was purchased at an average cost of $4.32 per share, for a total transaction of $86,400.00. Following the completion of the acquisition, the director now owns 61,380 shares in the company, valued at $265,161.60. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 44,722 shares of company stock worth $195,676. Insiders own 4.10% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new position in shares of Endologix during the first quarter worth approximately $160,000. Emerald Advisers Inc. PA purchased a new position in shares of Endologix during the first quarter worth approximately $222,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Endologix during the first quarter worth approximately $261,000. MARSHALL WACE ASIA Ltd purchased a new position in shares of Endologix during the first quarter worth approximately $323,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Endologix during the first quarter worth approximately $323,000.
Shares of Endologix (NASDAQ ELGX) opened at 4.89 on Tuesday. Endologix has a 52-week low of $4.20 and a 52-week high of $13.96. The company’s market capitalization is $405.75 million. The stock has a 50 day moving average price of $4.92 and a 200 day moving average price of $6.08.
COPYRIGHT VIOLATION WARNING: “Endologix, Inc. (NASDAQ:ELGX) Expected to Post Quarterly Sales of $47.67 Million” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/endologix-inc-nasdaqelgx-expected-to-post-quarterly-sales-of-47-67-million-updated-updated.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.